Search results
30 mar 2022 · Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 μg per kilogram of body...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
We enrolled 654 patients in the BRAVE-AA1 trial and 546 in...
- Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith
A 53-year-old landscaper presented with a 4-month history of...
- Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay
Interview with Kushal Kadakia on the 21st Century Cures Act,...
- Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes
19. Traeger AC, Henschke N, Hübscher M, et al. Estimating...
- Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries
Convalescent Plasma for Covid-19 — Making Sense of the...
- Clinical Problem-Solving Looking Back L. Glick and Others
Treatment with allopurinol at a dose of 50 mg daily was...
- Correspondence Dec 15, 2022 Ivermectin Treatment for Covid-19
Given the wide availability and low cost of ivermectin and...
- Editorial Audio Interview
In this audio interview conducted on May 2, 2022, the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
30 mar 2024 · The effect of ivermectin (IVM) in treating coronavirus disease 2019 (COVID-19) is still controversial, yet the drug has been widely used in the world. The aim of this review was to systematically evaluate the clinical outcomes of IVM in patients with COVID-19.
17 cze 2021 · A concentration dependent antiviral effect of ivermectin in COVID-19 was identified, with significant reductions in SARS-CoV-2 viral load in respiratory secretions among patients achieving high systemic ivermectin concentration compared to untreated controls.
12 paź 2020 · The article by Ceplowicz Rajter et al1 published in CHEST (January 2021), which presents a significant effect of ivermectin at standard dose on COVID-19 mortality rates, raises once again important questions on the significance of observational studies that report posttreatment outcome for COVID-19.
14 gru 2022 · Given the wide availability and low cost of ivermectin and that the dosage used in the trial appeared to be safe, such treatment effects could be an important benefit for high-risk patients who do...
introducing ivermectin as a treatment for COVID-19 patients was (and is) not justified. We currently are coordinating a randomized, Phase 2, double-blind clinical trial on ivermectin at high dose (600 or 1200 mg/kg for 5 consecutive days) for COVID-19 early stage in patients with mild symptoms who do not need hospitalization.5 We did not even ...
A single dose of ivermectin was well-tolerated in symptomatic patients with COVID-19, and important clinical features of COVID-19 were improved with ivermectin use, including dyspnea, cough, and lymphopenia.
